Wise Therapeutics was founded by Dr. Dennis-Tiwary and Raj Amin to transform breakthrough science into accessible and engaging digital therapeutics, such as Personal Zen. It was announced Wise Therapeutics intends to pursue FDA clearance across three target indications; alcohol use disorder, multiple sclerosis-related anxiety, and perinatal anxiety. This decision follows the success of three clinical trials which demonstrated the efficacy and impact of Wise’s core attention bias modification (ABM) engine across these indications.
Topline results from the three clinical trials included:
To read more about Wise Therapeutics, click here.
To learn about Personal Zen, click here.